AG
SUPN icon

Advisor Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Advisor Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$9K Sell
367
-688
-65% -$16.7K ﹤0.01% 4430
2019
Q3 		$28K Sell
1,055
-606
-36% -$18K ﹤0.01% 3756
2019
Q2 		$54K Sell
1,661
-1,442
-46% -$49.4K ﹤0.01% 3306
2019
Q1 		$110K Buy
3,103
+1,021
+49% +$38K ﹤0.01% 2777
2018
Q4 		$69K Buy
2,082
+306
+17% +$13.2K ﹤0.01% 2959
2018
Q3 		$90K Sell
1,776
-12,218
-87% -$603K ﹤0.01% 2833
2018
Q2 		$837K Buy
13,994
+11,530
+468% +$597K 0.01% 971
2018
Q1 		$112K Sell
2,464
-837
-25% -$34.9K ﹤0.01% 2474
2017
Q4 		$132K Buy
3,301
+230
+7% +$9.09K ﹤0.01% 2348
2017
Q3 		$123K Sell
3,071
-324
-10% -$14K ﹤0.01% 2243
2017
Q2 		$146K Buy
3,395
+410
+14% +$14.6K ﹤0.01% 2013
2017
Q1 		$95K Sell
2,985
-410
-12% -$11K ﹤0.01% 2198
2016
Q4 		$85K Sell
3,395
-391
-10% -$8.74K ﹤0.01% 2191
2016
Q3 		$94K Sell
3,786
-3,444
-48% -$77.9K ﹤0.01% 2050
2016
Q2 		$147K Buy
+7,230
New +$128K ﹤0.01% 1674

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisor Group's SUPN Position: Q4 2019 in Review

Advisor Group reduced its Supernus Pharmaceuticals (SUPN) stake by 65% in Q4 2019, selling an estimated $16.7K and leaving 367 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #4430.

Advisor Group first reported a position in SUPN in Q2 2016 and has held it in 15 quarters since. The position peaked at $837K in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

  • Advisor Group held 367 shares of Supernus Pharmaceuticals worth $9K as of Q4 2019.
  • Advisor Group sold 688 Supernus Pharmaceuticals shares in Q4 2019, an estimated $16.7K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4430 holding.
  • Advisor Group first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Supernus Pharmaceuticals position peaked at $837K in Q2 2018.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.